MARKET

OGEN

OGEN

ORAGENICS
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6820
-0.0180
-2.57%
Opening 13:31 09/22 EDT
OPEN
0.7000
PREV CLOSE
0.7000
HIGH
0.7100
LOW
0.6816
VOLUME
361.97K
TURNOVER
--
52 WEEK HIGH
2.090
52 WEEK LOW
0.3600
MARKET CAP
41.61M
P/E (TTM)
-1.3378
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Business Wire · 09/11 11:30
OGEN: SARS-CoV-2 Vaccine to Enter the Clinic in Early 2021
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Developing Vaccine Against SARS-CoV-2 In May 2020, Oragenics, Inc. (NYSE:OGEN) announced the acquisition of Noachis Terra Inc., which is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes
Zacks Small Cap Research · 09/03 14:47
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
Business Wire · 08/20 13:30
Oragenics inks deal with Avid Bio for advancement of COVID-19 vaccine
Oragenics (OGEN) soars 24% premarket after entering into a process development and drug substance manufacturing agreement with Avid Bioservices (CDMO), up 5%.Under terms of the agreement, Avid will provide Oragenics with analytical method
Seekingalpha · 08/20 12:59
Ocugen and vTv Therapeutics among healthcare gainers; Vaxart leads the losers
Seeking Alpha · 07/27 15:02
INTC, NIO among premarket losers
Seeking Alpha - Article · 07/24 12:24
Mid-Afternoon Market Update: Gold Rises 1%; Verb Technology Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 0.31% to 26923.91 while the NASDAQ fell 0.09% to 10670.29. The S&P also rose, gaining 0.26% to 3,265.71.
Benzinga · 07/22 18:48
Oragenics rallies on encouraging data supporting potential COVID-19 vaccine
Nano cap Oragenics (NYSEMKT:OGEN) jumps 36% premarket on robust volume in reaction to its announcement that its in-licensed SARS-CoV-2 spike protein genera
seekingalpha · 07/22 18:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OGEN stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 6.33M
% Owned: 10.37%
Shares Outstanding: 61.00M
TypeInstitutionsShares
Increased
4
857.31K
New
5
128.78K
Decreased
2
2.71M
Sold Out
2
2.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.78%
Pharmaceuticals & Medical Research
-0.38%
Key Executives
Chairman/Director
Frederick Telling
President/Chief Executive Officer/Director
Alan Joslyn
Chief Financial Officer/Treasurer/Secretary
Michael Sullivan
Director
Kim Murphy
Independent Director
Alan Dunton
Independent Director
Robert Koski
Independent Director
Charles Pope
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average OGEN stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OGEN
Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.